Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Renhe Pharmacy CoSZSE:000650 -1.29%83 OCF Yield % is 10.01 as of Sep. 03, 2026, which is 26% above its 10-year median of 7.96. GuruFocus rates SZSE:000650 with a GF Score™ of 83/100 and a GF Value™ of ¥5.07 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Renhe Pharmacy Co ranks better than 79.1% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Renhe Pharmacy Co OCF Yield % Related Terms
Renhe Pharmacy Co OCF Yield % Historical Data
* Premium members only.
The historical data trend for Renhe Pharmacy Co's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Renhe Pharmacy Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renhe Pharmacy Co OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Renhe Pharmacy Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Renhe Pharmacy Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renhe Pharmacy Co (SZSE:000650) has a OCF Yield % of 10.01 as of Sep. 03, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Renhe Pharmacy Co and its competitors. This is 26% above median its historical median of 7.96. Over the past decade, Renhe Pharmacy Co's OCF Yield % has ranged from 3.06 to 14.51. According to the industry distribution chart, Renhe Pharmacy Co ranks #210 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 20.9%.
Is Renhe Pharmacy Co's OCF Yield % too high?
Renhe Pharmacy Co's current OCF Yield % of 10.01 is 26% above median its 10-year median of 7.96. Over the past 10 years, this metric has ranged from a low of 3.06 to a high of 14.51. The Drug Manufacturers industry median OCF Yield % is 3.39. Renhe Pharmacy Co's value of 10.01 is 195.3% above this industry median. Based on the distribution chart, Renhe Pharmacy Co ranks #210 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Renhe Pharmacy Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Renhe Pharmacy Co's OCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Renhe Pharmacy Co ranks #210 out of 1005 companies for OCF Yield %. This places Renhe Pharmacy Co in the top 21% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.39. Renhe Pharmacy Co's value of 10.01 is 195.3% above this benchmark. Historically, Renhe Pharmacy Co's own OCF Yield % has ranged from 3.06 to 14.51 over the past decade. While the company's 10-year median is 7.96 vs. the industry median of 3.39, Renhe Pharmacy Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.39, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renhe Pharmacy Co's current OCF Yield % of 10.01 is 195.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Renhe Pharmacy Co and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renhe Pharmacy Co's current OCF Yield % is 10.01, which is 26% above median its own 10-year median of 7.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renhe Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Renhe Pharmacy Co (SZSE:000650) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.07, compared to a current price of ¥5.37 — trading 5.9% above its estimated fair value. The current OCF Yield % is 10.01, which is 26% above median its 10-year median of 7.96 and 195.3% above the Drug Manufacturers industry median of 3.39. Renhe Pharmacy Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Renhe Pharmacy Co (SZSE:000650), the current OCF Yield % is 10.01 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renhe Pharmacy Co (SZSE:000650) Overvalued in 2026?
Based on GuruFocus' analysis, Renhe Pharmacy Co stock appears to be overvalued.
The current stock price of ¥5.37 is trading 5.9% above its estimated GF Value™ of ¥5.07.
GuruFocus considers Renhe Pharmacy Co to be Fairly Valued.
Key valuation signals for SZSE:000650:
OCF Yield %: 10.01 (26% above median its 10-year median of 7.96)
GF Value™: ¥5.07 vs. price of ¥5.37 (5.9% above fair value)
Industry Position: 195.3% above the Drug Manufacturers median (#210 of 1005)
No single metric tells the full story. See the SZSE:000650 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renhe Pharmacy Co Ltd is a China-based company engaged in the production and sale of Chinese and Western medicines, raw materials, and health-related products, including oral solid dosage forms, oral liquid dosage forms, large-volume injections, small-volume injections, external washes, liniments, suppositories, ointments, and other dosage forms of pharmaceuticals and health-related products. The company's main products include: Renhe Kelike, Youkadan series, Fuyanjie series, Da Huo Luo capsules, Shanliang eye drops, Qinghuo capsules, and Zhengwei capsules.
83GF Score
Get the complete analysis for SZSE:000650
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:000650 has been successfully added to your 
